References:
[1] S.B. Abdelaziz, Y.S. Galal,
A.S. Sedrak, D.S.J.J.o.D.M. Shaheen, Association of Hepatitis C Virus
Infection and Type 2 Diabetes in Egypt: A Hospital-Based Study, 6(01)
(2015) 77.
[2] J. McElnay, A. Nicholl,
T.J.J.I.J.o.P.P. Grainger‐Rousseau, The role of the community
pharmacist—a survey of public opinion in Northern Ireland, 2(2) (1993)
95-100.
[3] A.L. May, E.V. Kuklina,
P.W.J.P. Yoon, Prevalence of cardiovascular disease risk factors among
US adolescents, 1999− 2008, 129(6) (2012) 1035-1041.
[4] A. Elgharably, A.I. Gomaa,
M.M. Crossey, P.J. Norsworthy, I. Waked, S.D.J.I.j.o.g.m.
Taylor-Robinson, Hepatitis C in Egypt–past, present, and future, 10
(2017) 1.
[5] L. Benova, S.F. Awad, F.D.
Miller, L.J.J.H. Abu‐Raddad, Estimation of hepatitis C virus infections
resulting from vertical transmission in Egypt, 61(3) (2015) 834-842.
[6] A. Petruzziello, S.
Marigliano, G. Loquercio, A. Cozzolino, C.J.W.j.o.g. Cacciapuoti, Global
epidemiology of hepatitis C virus infection: An up-date of the
distribution and circulation of hepatitis C virus genotypes, 22(34)
(2016) 7824.
[7] H. Ayoub, L.J.J.J.o.v.h.
Abu‐Raddad, Impact of treatment on hepatitis C virus transmission and
incidence in Egypt: A case for treatment as prevention, 24(6) (2017)
486-495.
[8] W. El‐Akel, M. El‐Sayed, M. El
Kassas, M. El‐Serafy, M. Khairy, K. Elsaeed, K. Kabil, M. Hassany, A.
Shawky, A.J.J.o.v.h. Yosry, National treatment programme of hepatitis C
in Egypt: hepatitis C virus model of care, 24(4) (2017) 262-267.
[9] M. Lazo, C. Nwankwo, N.R.
Daya, D.L. Thomas, S.H. Mehta, S. Juraschek, K. Willis, E.J.C.G. Selvin,
Hepatology, Confluence of epidemics of hepatitis C, diabetes, obesity,
and chronic kidney disease in the United States population, 15(12)
(2017) 1957-1964. e7.
[10] D. Kralj, L.V. Jukić, S.
Stojsavljević, M. Duvnjak, M. Smolić, I.B.J.J.o.c. Čurčić, t.
hepatology, Hepatitis C virus, insulin resistance, and steatosis, 4(1)
(2016) 66.
[11] Y.-C. Tsao, J.-Y. Chen,
W.-C. Yeh, Y.-S. Peng, W.-C.J.B.o. Li, Association between visceral
obesity and hepatitis C infection stratified by gender: a
cross-sectional study in Taiwan, 7(11) (2017) e017117.
[12] L. Leon, S. Kasereka, F.
Barin, C. Larsen, L. Weill-Barillet, X. Pascal, S. Chevaliez, J.
Pillonel, M. Jauffret-Roustide, Y.J.E. Le Strat, Infection, Age-and
time-dependent prevalence and incidence of hepatitis C virus infection
in drug users in France, 2004–2011: model-based estimation from two
national cross-sectional serosurveys, 145(5) (2017) 895-907.
[13] P. Cacoub, C. Comarmond,
Considering hepatitis C virus infection as a systemic disease, Seminars
in dialysis, Wiley Online Library, 2019, pp. 99-107.
[14] A.-C. Desbois, P.J.W.j.o.g.
Cacoub, Diabetes mellitus, insulin resistance and hepatitis C virus
infection: A contemporary review, 23(9) (2017) 1697.
[15] W. Chehadeh, N. Abdella, A.
Ben‐Nakhi, M. Al‐Arouj, W.J.J.o.g. Al‐Nakib, hepatology, Risk factors
for the development of diabetes mellitus in chronic hepatitis C virus
genotype 4 infection, 24(1) (2009) 42-48.
[16] S.S. Hammerstad, S.F. Grock,
H.J. Lee, A. Hasham, N. Sundaram, Y.J.F.i.e. Tomer, Diabetes and
hepatitis C: a two-way association, 6 (2015) 134.
[17] A. Kassem¹, H.E.J.L.S.J.
Salah, Impact of Direct Acting Antivirals for Treatment of Chronic
Hepatitic C Virus Infection on Glycemic Control in Egyptian Patients
with Type 2 Diabetes Mellitus, 15(3) (2018).
[18] J. Hum, J.H. Jou, P.K.
Green, K. Berry, J. Lundblad, B.D. Hettinger, M. Chang, G.N.J.D.c.
Ioannou, Improvement in glycemic control of type 2 diabetes after
successful treatment of hepatitis C virus, 40(9) (2017) 1173-1180.
[19] H.K. Dyal, M. Aguilar, T.
Bhuket, B. Liu, E.W. Holt, S. Torres, R. Cheung, R.J.J.D.d. Wong,
sciences, Concurrent obesity, diabetes, and steatosis increase risk of
advanced fibrosis among HCV patients: a systematic review, 60(9) (2015)
2813-2824.
[20] A. Baecker, X. Liu, C.V. La,
Z.-F.J.E.j.o.c.p.t.o.j.o.t.E.C.P.O. Zhang, Worldwide incidence of
hepatocellular carcinoma cases attributable to major risk factors, 27(3)
(2018) 205-212.
[21] Z.A. Ali-Eldin, F.A.
Ali-Eldin, I.E.J.J.o.c. Mohamed, d.r. JCDR, Visceral Adiposity Index and
the Degree of Hepatic Fibrosis and Inflammation in Egyptian Patients
with Chronic Hepatitis C, 11(8) (2017) OC11.
[22] M. Gadallah, S. Kandil,
A.J.T.M. Mohsen, I. Health, Association between hepatitis C infection
and cerebro‐cardiovascular disease: analysis of a national
population‐based survey in Egypt, 23(7) (2018) 738-747.
[23] S. Petta, M. Maida, F.S.
Macaluso, M. Barbara, A. Licata, A. Craxì, C.J.G. Cammà, Hepatitis C
virus infection is associated with increased cardiovascular mortality: a
meta-analysis of observational studies, 150(1) (2016) 145-155. e4.
[24] A.A. Butt, P. Yan, A.
Shuaib, A.-B. Abou-Samra, O.S. Shaikh, M.S.J.G. Freiberg, Direct-acting
antiviral therapy for HCV infection is associated with a reduced risk of
cardiovascular disease events, 156(4) (2019) 987-996. e8.
[25] O. Osibogun, O. Ogunmoroti,
E.D. Michos, E. Spatz, B. Olubajo, K. Nasir, P. Madhivanan, W.J.J.o.v.h.
Maziak, HIV/HCV coinfection and the risk of cardiovascular disease: A
meta‐analysis, 24(11) (2017) 998-1004.
[26] J. Fernández‐Montero, P.
Barreiro, C. De Mendoza, P. Labarga, V.J.J.o.v.h. Soriano, Hepatitis C
virus coinfection independently increases the risk of cardiovascular
disease in HIV‐positive patients, 23(1) (2016) 47-52.
[27] S. Leone, M. Prosperi, S.
Costarelli, P. Nasta, F. Maggiolo, S. Di Giambenedetto, A. Saracino, M.
Di Pietro, A.J.E.J.o.C.M. Gori, I. Diseases, Incidence and predictors of
cardiovascular disease, chronic kidney disease, and diabetes in
HIV/HCV-coinfected patients who achieved sustained virological response,
35(9) (2016) 1511-1520.